A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II to IV (M0) Resectable Cutaneous Squamous Cell Carcinoma
Latest Information Update: 13 Jan 2025
At a glance
- Drugs Nivolumab/relatlimab (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Jan 2025 Status changed from not yet recruiting to recruiting.
- 18 Jun 2024 Planned End Date changed from 1 Apr 2036 to 1 Jul 2036.
- 18 Jun 2024 Planned primary completion date changed from 1 Jun 2026 to 1 Sep 2026.